Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.
Yi Qian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
A. Brett Hauber
Research Funding - Amgen
Juan Marcos Gonzalez
Research Funding - Amgen
Joshua Posner
Research Funding - Amgen
Ateesha F Mohamed
No relevant relationships to disclose
Bertrand Tombal
Consultant or Advisory Role - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Research Funding - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Expert Testimony - Amgen; Dendreon
Jean-Jacques Body
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Novartis
Francesca Gatta
Employment or Leadership Position - Amgen
Jorge Arellano
Employment or Leadership Position - Amgen
Stock Ownership - Amgen